PUBLISHER: Grand View Research | PRODUCT CODE: 1813969
PUBLISHER: Grand View Research | PRODUCT CODE: 1813969
The global induced pluripotent stem cells production market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 3.78 billion by 2033, growing at a CAGR of 10.01% from 2025 to 2033. The potential of stem cell-based therapies, the growing incidence of cancer, capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth significantly.
Expanding Role of iPSC-Derived Cells in Drug Discovery and Toxicology Screening
The use of induced pluripotent stem cell (iPSC)-derived cells in drug discovery and toxicology screening is emerging as a major growth driver for the iPSC production market. Pharma and biotech companies are increasingly adopting iPSC-derived cardiomyocytes, hepatocytes, and neuronal cells to create physiologically relevant in vitro models that better mimic human biology than conventional cell lines or animal models. These models enable high-throughput screening, improve early-stage safety and efficacy assessments, and align with the global push to reduce animal testing, meeting ethical and regulatory expectations.
Global Induced Pluripotent Stem Cells Production Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells production market report based on process, workflow, product, application, end use, and region: